Letter to the editor: Is the intratumor steatosis a novel biomarker for predicting the efficacy of immunotherapy in hepatocellular carcinoma?

Affiliations

Comment

Binghua Li et al. Hepatology. 2022 Dec.

. 2022 Dec;76(6):E131-E132.

doi: 10.1002/hep.32616. Epub 2022 Jun 22.

¹ Department of Hepatobiliary Surgery, the Affiliated Drum Tower HospitalMedical School of Nanjing UniversityNanjingChina.

No abstract available

Comment on

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, Shigematsu Y, Inamura K, Mise Y, Saiura A, Ono Y, Takahashi Y, Kawasaki Y, Iino S, Kobayashi S, Idogawa M, Tokino T, Hashidate-Yoshida T, Shindou H, Miyazaki M, Imai Y, Tanaka S, Mita E, Ohkawa K, Hikita H, Sakamori R, Tatsumi T, Eguchi H, Morii E, Takehara T. Murai H, et al. Hepatology. 2023 Jan 1;77(1):77-91. doi: 10.1002/hep.32573. Epub 2022 Jun 17. Hepatology. 2023. PMID: 35567547 Free PMC article.

1. Murai H, Kodama T, Maesaka K, Tange S, Motooka D, Suzuki Y, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology. 2022. https://doi.org/10.1002/hep.32573 - DOI
1. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014;147:754–64.
1. Howie D, Ten Bokum A, Cobbold SP, Yu Z, Kessler BM, Waldmann H. A novel role for triglyceride metabolism in Foxp3 expression. Front Immunol. 2019;10:1860.
1. Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M. Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology. 2014;64:951–62.